BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19

As part of the collaboration, the parties will use BioSymetrics’ Contingent-AI™ engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease.

Read More